Great Point Partners LLC Sells 79,635 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Great Point Partners LLC cut its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 19.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 322,380 shares of the company's stock after selling 79,635 shares during the quarter. Jasper Therapeutics accounts for approximately 1.8% of Great Point Partners LLC's holdings, making the stock its 20th largest position. Great Point Partners LLC owned approximately 2.13% of Jasper Therapeutics worth $6,064,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after purchasing an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC purchased a new position in Jasper Therapeutics in the 3rd quarter worth about $59,000. Virtu Financial LLC bought a new position in Jasper Therapeutics during the 1st quarter valued at about $306,000. Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at about $300,000. Finally, American Century Companies Inc. grew its stake in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock worth $322,000 after acquiring an additional 3,032 shares during the period. Institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Trading Up 2.7 %

NASDAQ JSPR traded up $0.61 on Wednesday, hitting $23.24. 185,249 shares of the company traded hands, compared to its average volume of 175,451. The business's 50 day moving average price is $20.26 and its 200-day moving average price is $20.87. The company has a market capitalization of $348.60 million, a price-to-earnings ratio of -4.95 and a beta of 2.19. Jasper Therapeutics, Inc. has a 52-week low of $4.00 and a 52-week high of $31.01.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JSPR shares. Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 14th. Evercore ISI reissued an "outperform" rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Jasper Therapeutics in a report on Monday, September 9th. JMP Securities reissued a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $74.86.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.